NCT07031154

A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 43 (estimated)
• Sponsor: The First Affiliated Hospital of Xiamen University · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the major pathological response rate of Adibelimab combined with Apatinib neoadjuvant therapy in resectable non-small cell lung cancer.

Conditions

• Non-Small Cell Lung Cancer
• Adebrelimab
• Apatinib

Interventions

Type	Name	Description
DRUG	Adebrelimab	Adebrelimab 1200mg, iv, D1，Q3W
DRUG	Apatinib	Apatinib 250mg，P.O，qd，Q3W

Timeline

• Start date: 2025-06-30
• Primary completion: 2027-02-01
• Completion: 2027-02-01
• First posted: 2025-06-22
• Last updated: 2025-06-22

Locations

1 site across 1 country: China